US2012172525A1PendingUtilityA1

Compositions containing inclusion complexes

Assignee: PUN SUZIE HWANGPriority: Dec 19, 2000Filed: Nov 28, 2011Published: Jul 5, 2012
Est. expiryDec 19, 2020(expired)· nominal 20-yr term from priority
A61P 35/04A61P 31/12A61P 9/00A61K 47/6949C08B 37/0012A61K 38/44C08G 65/33396A61K 47/555C08G 2650/38C12Y 113/12007A61K 48/0041A61K 47/6951C08G 65/48B82Y 5/00C08B 37/0015C08G 2650/04A61P 21/00A61K 47/50C12N 15/87
60
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention provides a composition containing particulate composite of a polymer and a therapeutic agent. The composition also contains a complexing agent. The polymer interacts with the complexing agent in a host-guest or a guest-host interaction to form an inclusion complex. A therapeutic composition of the invention may be used to deliver the therapeutic agent and to treat various disorders. Both the polymer of the particulate composite and the complexing agent may be used to introduce functionality into the therapeutic composition. The invention also relates to a method of preparing a composition. The method combines a therapeutic agent, a polymer having host or guest functionality, and a complexing agent having guest or host functionality to form the therapeutic composition. The complexing agent forms an inclusion complex with the polymer. The invention also relates to a method of delivering a therapeutic agent. According to the method, a therapeutically effective amount of a therapeutic composition of the invention is administered to a mammal (e.g. person or animal) in recognized need of the therapeutic. Also disclosed are compounds having the formula:

Claims

exact text as granted — not AI-modified
1 - 21 . (canceled) 
     
     
         22 . An adamantane derivative of the formula: 
       
         
           
           
               
               
           
         
       
       wherein
 J is —NH—, —C(═O)NH—(CH 2 ) d —, —NH—C(═O)—(CH 2 ) d —, —CH 2 SS—, —C(═O)O—(CH. 2 ) c —O—P(═O)(O—(CH 2 ) c -Ad)O—, 
 
       
         
           
           
               
               
           
         
       
       a peptide or polypeptide residue, or —NH(C═O)—CH(R 1 )—NH—(C═O)—CH(R 1 )—NH—;
 Ad is adamantyl; 
 R 1  is —(CH 2 ) a —CO 2 H, an ester or salt thereof; or 
 —(CH 2 ) a —CONH 2 ; 
 PEG is —O(CH 2 CH 2 O) z —, where z varies from 2 to 500; 
 L is H, —NH 2 , —NH—(C═O)—(CH 2 ), —(C═O)—CH 2 , —S(═O) 2 —HC═CH 2 —, —SS—, —C(═O)O— or a carbohydrate residue; 
 a is 0 or 1; 
 b is 0 or 1; 
 d ranges from 0 to 6; 
 e ranges from 1 to 6; 
 y is 0 or 1; and 
 x is 0 or 1.

Join the waitlist — get patent alerts

Track US2012172525A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.